LONDON, Aug. 30, 2018 /PRNewswire/ -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will be participating in the following, upcoming investor conferences:
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to: https://www.autolus.com
Investor Contact: |
International Media Contact: |
U.S. Media Contact: |
S.A. Noonan Communications, LLC |
JW Communications |
Rx Communications Group, LLC |
Susan A. Noonan |
Julia Wilson |
Paula Schwartz |
+1-212-966-3650 |
+44 (0)7818 430877 |
+ 1-917-322-2216 |
SOURCE Autolus Therapeutics plc